A Phase 1/2 interventional study of TTP399 and TTP399 in Diabetes Mellitus, Type 1, sponsored by vTv Therapeutics. Completed at 15 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-07-03.
Sponsored by vTv Therapeutics · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States — 191 open to participants now, 259 under way, 17 of them phase 3. Diabetes Mellitus, Type 1 · United States.
Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, this one is the 299th largest by enrollment of the 1,242 interventional ones that give a count, is one of 76 that started in 2017, is one of 59 in phase 1/2, and was the 807th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →191 of the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States are open now. Recruiting first, the newest first:
Emory University · Sites in United States
Ages 31–75 · Healthy volunteers
University of California, Los Angeles · Sites in United States
Ages 18+
University of Florida · Sites in United States
Ages 5–40
Wayne State University · Sites in United States
Ages 16–20
Medtronic MiniMed, Inc. · Sites in United States
Ages 2–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,458 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 206 · Phase 2 267 · Phase 3 167 · Phase 4 74
First in 1983; this study’s year is marked. 76 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 115 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 40 across the 1,242 interventional studies, 64 across the 203 observational. Of the 1,117 that completed or were terminated, 563 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
398 of 1,458 have an industry lead sponsor. The 10 most frequent:
vTv Therapeutics is the lead sponsor of 14 studies on the registry; 1 is open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
vTv Therapeutics has 3 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
117 of the studies in Diabetes Mellitus, Type 1 with a site in United States that are under way reach primary completion within a year, 7 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07076199Phase 3Novo Nordisk A/SA Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes | 2027-01-25 |
| NCT06334133Phase 3vTv TherapeuticsCadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes | 2027-04 |
| NCT07056699Phase 3The University of Texas Health Science Center at San AntonioSGLT2i, Pioglitazone, and Ketone Production in T1D | 2027-06-01 |
Add all 117 to your calendar (.ics) → With an account.
Among the 1,458 studies in Diabetes Mellitus, Type 1 with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and efficacy of TTP399 in Type 1 diabetics. This study will be in 2 phases: phase 1 will evaluate the safety of different TTP399 dosage regimens over 1 week of daily dosing. Phase 2 will evaluate the safety and efficacy of a TTP399 dosing regimen over 12 weeks of daily dosing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: TTP399
Drug: Placebo Oral Tablet
Phase 1: Participants will receive TTP399 administered orally up to 1200 mg taken once daily for 7 days
Phase 2: Participants will receive TTP399 administered orally 800 mg taken once daily for 12 weeks
Phase 2: Participants will receive Placebo oral tablets for 12 weeks
Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12
To evaluate the change in glycosylated hemoglobin (HbA1C) in Part 1 and Part 2 participants following multiple-day dosing (at 12 weeks) in subjects with T1MD. Sentinel participants were not evaluated for a change in HbA1C.
Time frame: Baseline (Day 1) to Week 13
Sentinel - Area Under the Concentration Time Curve (AUC)
AUC for Day 1 per dose level (400 mg, 800 mg, and 1200 mg) is AUC from 0 to 9 hours.
Time frame: Predose, 60, 90, 120, 150, 180, 240, 360 (6hr) and 540min (9hr) after dosing.
Sentinel - Maximum Drug Concentration (Cmax)
Time frame: Predose, 60, 90, 120, 150, 180, 240, 360 (6hr) and 540min (9hr) after dosing.
Sentinel - Time to Maximum Concentration (Tmax)
Time frame: Predose, 60, 90, 120, 150, 180, 240, 360 (6hr) and 540min (9hr) after dosing.
Percent Change From Baseline Time in Target Glycemic Range (70-180 mg/dL)
To evaluate the change from baseline time in target range (24 hour)
Time frame: Baseline (Day 1) to Week 12
Percent Change From Baseline Time in Hypoglycemia (< 54 mg/dL)
To evaluate the change from baseline time in hypoglycemia (\< 54 mg/dL)
Time frame: Baseline (Day 1) to Week 12
Percent Change From Baseline Time in Hypoglycemia (< 70 mg/dL)
To evaluate the change from baseline time in hypoglycemia (\< 70 mg/dL)
Time frame: Baseline (Day 1) to Week 12
Percent Change From Baseline Time in Hyperglycemia (>180 mg/dL)
To evaluate the change from baseline time in hypoglycemia (\>180 mg/dL)
Time frame: Baseline (Day 1) to Week 12
Percent Change From Baseline Time in Hyperglycemia (>250 mg/dL)
To evaluate the change from baseline time in hypoglycemia (\>250 mg/dL)
Time frame: Baseline (Day 1) to Week 12
Percent Change From Baseline in Total Daily Insulin Use
To evaluate the percent change from baseline in total daily insulin use at week 12.
Time frame: Baseline (Day 1) to Week 12
Change From Baseline in Bolus Insulin Use
To evaluate the change from baseline in bolus insulin use
Time frame: Baseline (Day 1) to Week 12
Change From Baseline in Basal Insulin Use
To evaluate the change from baseline in basal insulin use
Time frame: Baseline (Day 1) to Week 12
| Milestone | Sentinels | Part 1 TTP399 800 mg | Part 1 Placebo | Part 2 TTP399 800 mg | Part 2 Placebo |
|---|---|---|---|---|---|
| Started | 5 | 9 | 11 | 40 | 45 |
| Completed | 5 | 9 | 10 | 40 | 43 |
| Not completed | 0 | 0 | 1 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Randomization error | 0 | 0 | 1 | 0 | 0 |
To evaluate the change in glycosylated hemoglobin (HbA1C) in Part 1 and Part 2 participants following multiple-day dosing (at 12 weeks) in subjects with T1MD. Sentinel participants were not evaluated for a change in HbA1C.
| percent change | Part 1 Placebo | Part 1 TTP399 800 mg | Part 2 Placebo | Part 2 TTP399 800 mg |
|---|---|---|---|---|
| Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 | 0.08 ± 0.2 | -0.60 ± 0.2 | 0.07 ± 0.06 | -0.14 ± 0.06 |
AUC for Day 1 per dose level (400 mg, 800 mg, and 1200 mg) is AUC from 0 to 9 hours.
| ng*h/mL | Sentinel 400 mg | Sentinel 800 mg | Sentinel 1200 mg |
|---|---|---|---|
| Sentinel - Area Under the Concentration Time Curve (AUC) | 1778 ± 992 | 1482 ± 341 | 4848 ± 2663 |
| ng/mL | Sentinel 400 mg | Sentinel 800 mg | Sentinel 1200 mg |
|---|---|---|---|
| Sentinel - Maximum Drug Concentration (Cmax) | 645 ± 219 | 813 ± 129 | 2038 ± 1415 |
To evaluate the change from baseline time in target range (24 hour)
| percent change | Part 1 Placebo | Part 1 TTP399 800 mg | Part 2 Placebo | Part 2 TTP399 800 mg |
|---|---|---|---|---|
| Percent Change From Baseline Time in Target Glycemic Range (70-180 mg/dL) | -8 ± 10 | -3 ± 8 | -7 ± 14.0 | 0.50 ± 16 |
To evaluate the change from baseline time in hypoglycemia (\< 54 mg/dL)
| percent change | Part 1 Placebo | Part 1 TTP399 800 mg | Part 2 Placebo | Part 2 TTP399 800 mg |
|---|---|---|---|---|
| Percent Change From Baseline Time in Hypoglycemia (< 54 mg/dL) | -0.1 (-2 to 2) | -0.1 (-3 to 0) | -0.5 (-8 to 8) | -0.5 (-8 to 22) |
To evaluate the change from baseline time in hypoglycemia (\< 70 mg/dL)
| percent change | Part 1 Placebo | Part 1 TTP399 800 mg | Part 2 Placebo | Part 2 TTP399 800 mg |
|---|---|---|---|---|
| Percent Change From Baseline Time in Hypoglycemia (< 70 mg/dL) | -1 ± 3 | -1 ± 3 | -2 ± 5 | -2 ± 8 |
To evaluate the change from baseline time in hypoglycemia (\>180 mg/dL)
| percent change | Part 1 Placebo | Part 1 TTP399 800 mg | Part 2 Placebo | Part 2 TTP399 800 mg |
|---|---|---|---|---|
| Percent Change From Baseline Time in Hyperglycemia (>180 mg/dL) | 9 ± 12 | 5 ± 8 | 10 ± 17 | 1 ± 18 |
To evaluate the change from baseline time in hypoglycemia (\>250 mg/dL)
| percent change | Part 2 Placebo | Part 2 TTP399 800 mg |
|---|---|---|
| Percent Change From Baseline Time in Hyperglycemia (>250 mg/dL) | 6 ± 11 | 2 ± 12 |
To evaluate the percent change from baseline in total daily insulin use at week 12.
| percent change | Part 1 Placebo | Part 1 TTP399 800 mg | Part 2 Placebo | Part 2 TTP399 800 mg |
|---|---|---|---|---|
| Percent Change From Baseline in Total Daily Insulin Use | -0.1 ± 8.7 | -1.7 ± 14.7 | -1.6 ± 16 | -7.6 ± 10.1 |
To evaluate the change from baseline in bolus insulin use
| units/kg/day | Part 1 Placebo | Part 1 TTP399 800 mg | Part 2 Placebo | Part 2 TTP399 800 mg |
|---|---|---|---|---|
| Change From Baseline in Bolus Insulin Use | -5.9 ± 17.5 | -1 ± 31.8 | -3.9 ± 28.4 | -8.4 ± 22.7 |
To evaluate the change from baseline in basal insulin use
| units/kg/day | Part 1 Placebo | Part 1 TTP399 800 mg | Part 2 Placebo | Part 2 TTP399 800 mg |
|---|---|---|---|---|
| Change From Baseline in Basal Insulin Use | 4.4 ± 7.7 | -2.3 ± 10.3 | -0.5 ± 11.6 | -5.4 ± 7.1 |
| hour | Sentinel 400 mg | Sentinel 800 mg | Sentinel 1200 mg |
|---|---|---|---|
| Sentinel - Time to Maximum Concentration (Tmax) | 1.5 (1.5 to 2.5) | 1.5 (1.5 to 2.0) | 2.5 (1.5 to 3.0) |
Collected over Treatment-emergent adverse events were those reported at baseline up to 12 weeks (±3) days after the last dose. Unresolved AEs were followed up by the investigator for as long as medically indicated. Sentinel group reported at baseline up to 28 days after the last dose.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sentinel 400 mg | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| Sentinel 800 mg | 0/5 (0%) | 0/5 (0%) | 1/5 (20%) |
| Sentinel 1200 mg | 0/5 (0%) | 0/5 (0%) | 2/5 (40%) |
| Placebo (Part 1 and Part 2) | 0/56 (0%) | 1/56 (1.8%) | 32/56 (57.1%) |
| TTP399 800 mg (Part 1 and Part 2) | 0/49 (0%) | 1/49 (2%) | 25/49 (51%) |
| Event | Sentinel 400 mg | Sentinel 800 mg | Sentinel 1200 mg | Placebo (Part 1 and Part 2) | TTP399 800 mg (Part 1 and Part 2) |
|---|---|---|---|---|---|
| Non-Cardiac Chest PainGeneral disorders | 0/5 | 0/5 | 0/5 | 0/56 | 1/49 |
| Coronary Artery DiseaseCardiac disorders | 0/5 | 0/5 | 0/5 | 1/56 | 0/49 |
| Event | Sentinel 400 mg | Sentinel 800 mg | Sentinel 1200 mg | Placebo (Part 1 and Part 2) | TTP399 800 mg (Part 1 and Part 2) |
|---|---|---|---|---|---|
| HypoglycemiaMetabolism and nutrition disorders | 2/5 | 0/5 | 0/5 | 9/56 | 5/49 |
| NauseaGastrointestinal disorders | 0/5 | 0/5 | 1/5 | 4/56 | 3/49 |
| HypocalcemiaMetabolism and nutrition disorders | 0/5 | 1/5 | 0/5 | 0/56 | 0/49 |
| Right Eye DiscomfortEye disorders | 0/5 | 0/5 | 1/5 | 0/56 | 0/49 |
| HeadacheNervous system disorders | 1/5 | 0/5 | 0/5 | 2/56 | 0/49 |
| Upper respiratory tract infectionInfections and infestations | 0/5 | 0/5 | 0/5 | 6/56 | 7/49 |
| Urinary tract infectionInfections and infestations | 0/5 | 0/5 | 0/5 | 4/56 | 0/49 |
| NasopharyngitisInfections and infestations | 0/5 | 0/5 | 0/5 | 3/56 | 3/49 |
| Ear infectionInfections and infestations | 0/5 | 0/5 | 0/5 | 0/56 | 3/49 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/5 | 0/5 | 0/5 | 3/56 | 2/49 |
Sentinel participants were the same participants throughout the dose levels. Part 1 is the full analysis set. Part 2 is all randomized subjects who received at least 1 dose of the investigational product.
| Age, Continuous(years) | Sentinel | Part 1 TTP399 800 mg | Part 1 Placebo | Part 2 TTP399 800 mg | Part 2 Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 32 ± 7.4 | 38 ± 15.71 | 47 ± 10.10 | 43 ± 15.26 | 42 ± 13.26 | 42.5 ± 13.76 |
| Sex: Female, Male(Participants) | Sentinel | Part 1 TTP399 800 mg | Part 1 Placebo | Part 2 TTP399 800 mg | Part 2 Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 3 | 5 | 8 | 15 | 25 | 56 |
| Male | 2 | 3 | 3 | 25 | 20 | 53 |
| Ethnicity (NIH/OMB)(Participants) | Sentinel | Part 1 TTP399 800 mg | Part 1 Placebo | Part 2 TTP399 800 mg | Part 2 Placebo | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 1 | 2 | 3 |
| Not Hispanic or Latino | 5 | 8 | 11 | 39 | 43 | 106 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Sentinel | Part 1 TTP399 800 mg | Part 1 Placebo | Part 2 TTP399 800 mg | Part 2 Placebo | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 0 | 1 | 2 |
| White | 5 | 7 | 11 | 38 | 43 | 104 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| BMI(kg/m2) | Sentinel | Part 1 TTP399 800 mg | Part 1 Placebo | Part 2 TTP399 800 mg | Part 2 Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 24 ± 3 | 28 ± 3.30 | 29 ± 4.13 | 28 ± 4.16 | 28 ± 3.76 | 28 ± 3.8 |
| Glycosylated hemoglobin (HbA1c)(Percent HbA1c in blood) | Sentinel | Part 1 TTP399 800 mg | Part 1 Placebo | Part 2 TTP399 800 mg | Part 2 Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 6.9 ± 0.7 | 7.20 ± 0.42 | 7.36 ± 0.41 | 7.66 ± 0.56 | 7.52 ± 0.59 | 7.45 ± 0.7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2017 to primary completion in Dec 2019, 25 months.
Results were first posted in Jul 2023, 3 years 6 months after primary completion. A results delay was requested in Nov 2020.
Of 44 phase 1/2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 93. This study's 25 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TTP399
vTv Therapeutics